We are live on ! Find out more
PRVL

Prevail Therapeutics Inc. Common Stock
PRVL

Delisted

PRVL was delisted on the 21st of January, 2021.

Back to rankings

93 hedge funds and large institutions have $648M invested in Prevail Therapeutics Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 41 funds opening new positions, 16 increasing their positions, 27 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

115% more capital invested

Capital invested by funds: $302M → $648M (+$346M)

71% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 24

22% more funds holding

Funds holding: 76 → 93 (+17)

41% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 27

77% less call options, than puts

Call options by funds: $3.68M | Put options by funds: $15.8M

Holders
93
Holders Change
+17
Holders Change %
+22.37%
% of All Funds
1.65%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.04%
New
41
Increased
16
Reduced
27
Closed
24
Calls
$3.68M
Puts
$15.8M
Net Calls
-$12.1M
Net Calls Change
-$12.1M

Top Buyers

Rank Fund Capital Flow
1
AAM
Alpine Associates Management
Florida
+$10.9M
2
TAL
TIG Advisors LLC
New York
+$8.99M
3
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$7.55M
4
Millennium Management
Millennium Management
New York
+$6.64M
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$3.52M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$19.5M
2
HighTower Advisors
HighTower Advisors
Illinois
-$11.5M
3
BlackRock
BlackRock
New York
-$9.81M
4
Morgan Stanley
Morgan Stanley
New York
-$7.86M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$6.87M
Name Holding Trade Value Shares
Change 		Change in
Stake
Point72 Asset Management
101
Point72 Asset Management
Connecticut
– -$1.6M -157,335 Closed
Renaissance Technologies
102
Renaissance Technologies
New York
– -$897K -88,100 Closed
MAM
103
Martingale Asset Management
Massachusetts
– -$404K -39,608 Closed
Allianz Asset Management
104
Allianz Asset Management
Germany
– -$366K -36,000 Closed
Ensign Peak Advisors
105
Ensign Peak Advisors
Utah
– -$286K -28,143 Closed
TI
106
Trexquant Investment
Connecticut
– -$203K -19,910 Closed
CCM
107
CAAS Capital Management
New York
– -$175K -17,200 Closed
Jane Street
108
Jane Street
New York
– -$125K -12,286 Closed
MIH
109
Meitav Investment House
Israel
– -$122K -12,000 Closed
ED
110
Exane Derivatives
France
– -$37.7K -3,700 Closed
US Bancorp
111
US Bancorp
Minnesota
– -$6K -600 Closed
ASN
112
Advisory Services Network
Georgia
– -$4K -400 Closed
CSS
113
Cubist Systematic Strategies
Connecticut
– -$3K -300 Closed
TPWA
114
TRUE Private Wealth Advisors
Oregon
– -$2K -200 Closed
IRC
115
Investors Research Corp
Georgia
– -$1K -62 Closed
Simplex Trading
116
Simplex Trading
Illinois
– +$1.53K +121 New
1 2 3 4
5

PRVL Hedge Fund Activity: Q4 2020 in Review

93 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Prevail Therapeutics Inc. Common Stock (PRVL) for Q4 2020, worth a combined $648M — up 115% from $302M a quarter earlier.

Buyers outnumbered sellers: 41 funds opened new PRVL positions and 24 closed out — a net gain of 17 holders — while 16 added to existing stakes and 27 trimmed.

The largest buyer was Alpine Associates Management, opening a new position worth an estimated $10.9M. The largest seller was RA Capital Management, exiting entirely with an estimated $19.5M sold.

  • 93 institutional investors held Prevail Therapeutics Inc. Common Stock (PRVL) as of Q4 2020, up from 76 in Q3 2020.
  • Funds reported $648M of Prevail Therapeutics Inc. Common Stock stock for Q4 2020, up 115% quarter-over-quarter.
  • 41 funds opened new Prevail Therapeutics Inc. Common Stock positions in Q4 2020 and 24 closed out, a net change of +17 holders.
  • The largest Prevail Therapeutics Inc. Common Stock buyer in Q4 2020 was Alpine Associates Management, an estimated $10.9M added.
  • The largest Prevail Therapeutics Inc. Common Stock seller in Q4 2020 was RA Capital Management, an estimated $19.5M sold.

Based on aggregated 13F filings for Q4 2020.